To include your compound in the COVID-19 Resource Center, submit it here.

Avastin, Lucentis equal in five-year AMD study

In an Avastin bevacizumab or Lucentis ranibizumab . The researchers highlighted the "remarkable" maintenance of visual acuity relative to outcomes prior to the development of anti-VEGF therapies such as Avastin and Lucentis.

Roche (SIX:ROG; OTCQX:RHHBY)

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE